Weekly Analysts’ Ratings Changes for Alignment Healthcare (ALHC)

Several brokerages have updated their recommendations and price targets on shares of Alignment Healthcare (NASDAQ: ALHC) in the last few weeks:

• 11/8/2025 – Alignment Healthcare was upgraded by analysts at Wall Street Zen from a “hold” rating to a “buy” rating.
• 11/5/2025 – Alignment Healthcare had its price target raised by analysts at JPMorgan Chase & Co. from $17.00 to $18.00. They now have a “neutral” rating on the stock.
• 11/3/2025 – Alignment Healthcare had its “buy” rating reaffirmed by analysts at The Goldman Sachs Group, Inc.. They now have a $22.00 price target on the stock.
• 10/31/2025 – Alignment Healthcare had its price target raised by analysts at Barclays PLC from $13.00 to $18.00. They now have an “equal weight” rating on the stock.
• 10/31/2025 – Alignment Healthcare had its price target raised by analysts at UBS Group AG from $17.00 to $18.00. They now have a “neutral” rating on the stock.
• 10/28/2025 – Alignment Healthcare was downgraded by analysts at Zacks Research from a “strong-buy” rating to a “hold” rating.
• 10/14/2025 – Alignment Healthcare is now covered by analysts at The Goldman Sachs Group, Inc.. They set a “buy” rating and a $21.00 price target on the stock.
• 10/14/2025 – Alignment Healthcare is now covered by analysts at The Goldman Sachs Group, Inc.. They set a “buy” rating and a $21.00 price target on the stock.
• 10/8/2025 – Alignment Healthcare had its “sell (d-)” rating reaffirmed by analysts at Weiss Ratings.
• 9/29/2025 – Alignment Healthcare was upgraded by analysts at Zacks Research from a “hold” rating to a “strong-buy” rating.
• 9/27/2025 – Alignment Healthcare had its “sell (d-)” rating reaffirmed by analysts at Weiss Ratings.

Insider Transactions at Alignment Healthcare

In other Alignment Healthcare news, CEO John E. Kao sold 180,000 shares of the business’s stock in a transaction dated Monday, November 10th. The shares were sold at an average price of $16.32, for a total value of $2,937,600.00. Following the completion of the transaction, the chief executive officer directly owned 2,526,726 shares of the company’s stock, valued at approximately $41,236,168.32. The trade was a 6.65% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director Joseph S. Konowiecki sold 4,832 shares of the stock in a transaction that occurred on Tuesday, November 11th. The shares were sold at an average price of $16.49, for a total transaction of $79,679.68. Following the sale, the director directly owned 1,081,141 shares in the company, valued at $17,828,015.09. This trade represents a 0.44% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last ninety days, insiders have sold 7,593,948 shares of company stock worth $122,396,905. Corporate insiders own 6.60% of the company’s stock.

Alignment Healthcare, Inc, a tech-enabled Medicare advantage company, operates consumer-centric health care platform for seniors in the United States. It provides customized health care designed to meet the needs of a diverse array of seniors through its Medicare advantage plans. The company was founded in 2013 and is based in Orange, California.